Subscribe Now Subscribe Today
Science Alert
Curve Top
Trends in Medical Research
  Year: 2007 | Volume: 2 | Issue: 3 | Page No.: 128-134
DOI: 10.3923/tmr.2007.128.134
Facebook Twitter Digg Reddit Linkedin StumbleUpon E-mail

Specificity of Serum Tumor Markers (CA125, CEA, AFP, Beta HCG) in Ovarian Malignancies

Rama Mani and Kaiser Jamil

The aim of present study was to investigate the role of serum CA125 in patients with ovarian cancer. Ovarian cancers comprise of heterogeneous group of malignancies arising from epithelial cells/mesencymal cells or germ cells. Present study included 100 patients who were diagnosed as epithelial ovarian carcinomas (75 cases), mucinous adeno carcinoma of ovary (20 cases) and germ cell ovarian carcinomas (05 cases). Upon presentation, all these cases were generally diagnosed using CA125; however other serum tumor markers were also used in this study to determine the specificity of the disease. Ninty percent of cases showed elevated levels of CA125, about 10-15% of cases showed specificity towards other serum markers like CEA, AFP and beta HCG. The survival period as monitored by these tumor markers ranged from 5-60 months being inversely proportional to the levels of CA125. Diagnosis with various tumor markers was useful in determining various sub types of ovarian cancers. It is concluded that the specificity of each type of tumor marker is typical for each subtype; however it is important to use more than one tumor marker to determine accurately the diagnostic and prognostic status of the cases.
PDF Fulltext XML References Citation Report Citation
How to cite this article:

Rama Mani and Kaiser Jamil , 2007. Specificity of Serum Tumor Markers (CA125, CEA, AFP, Beta HCG) in Ovarian Malignancies. Trends in Medical Research, 2: 128-134.

DOI: 10.3923/tmr.2007.128.134






Curve Bottom